Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Prevalence of impaired glucose metabolism in β-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy

Abstract

A cross-sectional study of impaired glucose metabolism was carried out in 48 β-thalassemic patients receiving hypertransfusions. An oral glucose tolerance test (OGTT) was performed using the method and criteria of the American Diabetes Association (ADA). Diabetes mellitus was diagnosed in two patients, and impaired glucose tolerance was found in four patients, giving a prevalence of impaired glucose metabolism of 12.5% in our patient population. The significant clinical characteristics associated with the diagnosis of impaired glucose metabolism were wasting (−2.15/−0.86 SDS, p = 0.025), stunting (−2.69/−1.22 SDS, p = 0.03), higher ferritin levels (8679/4710 μg/L, p = 0.005), splenectomy (50/9.5%, p = 0.012), and lower area under curve (AUC) of insulin secretion after OGTT (40.0/77.7, p = 0.002). The significant decrease of AUC insulin in thalassemic patients with an impaired glucose tolerance test suggests that the pathogenesis may originate from pancreatic β-cell damage rather than from insulin resistance. In conclusion, the prevalence of impaired glucose tolerance in our population of thalassemic patients receiving hypertransfusions with suboptimal iron chelating therapy was 12.5%. The clinical characteristics of thalassemic patients who developed impaired glucose tolerance were wasting, stunting, higher ferritin levels, splenectomy, and lower AUC insulin.

This is a preview of subscription content, log in to check access.

Abbreviations

ADA:

American Diabetes Association

DM:

diabetes mellitus

IFG:

impaired fasting glucose

IGT:

impaired glucose tolerance

NGT:

normal glucose tolerance

OGTT:

oral glucose tolerance test

References

  1. 1.

    American Diabetes Association (2007) Standards of medical care in diabetes - 2007. Diabetes Care 30[Suppl 1]:1183–1197

  2. 2.

    Arrigo T, Crisafulli G, Meo A, Sturiale M, Lombardo F, Miceli M, Cucinotta D, De Luca F (1998) Glucose tolerance, insulin secretion and peripheral sensitivity in thalassemia major. J Pediatr Endocrinol Metab 11:863–866

  3. 3.

    Borgna-Pignatti C, Cappellini MD, de Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A (2005) Survival and complications in thalassemia. Ann N Y Acad Sci 1054:40–47

  4. 4.

    Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW (1994) Efficacy of desferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567–573

  5. 5.

    Cario H, Stahnke K, Sander S, Kohne E (2000) Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study. Ann Hematol 79:7–12

  6. 6.

    Cavallo-Perin P, Pacini G, Cerutti F, Bessone A, Condo C, Sacchetti L, Piga A, Pagano G (1995) Insulin resistance and hyperinsulinemia in homozygous β-thalassemia. Metabolism 44:281–286

  7. 7.

    Chern JPS, Lin K-S, Lin K-H, Chen J-D, Lu M-Y, Fu C-C, Lin D-T (2001) Abnormal glucose tolerance in transfusion dependent β-thalassemia patients. Diab Care 24:850–854

  8. 8.

    De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC (2006) Impact of long-term iron chelation therapy on growth and endocrine functions in thalassemia. J Pediatr Endocrinol Metab 19:478–480

  9. 9.

    De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F (1988) Insulin dependent diabetes in thalassemia. Arch Dis Child 63:58–62

  10. 10.

    Fargion S, Taddei MT, Gabutti V, Piga A, Di Palma A, Capra L, Fontanelli G, Avanzini A (1982) Early iron overload in beta-thalassemia major: when to start chelation therapy? Arch Dis Child 57:929–933

  11. 11.

    Flynn DM, Fairney A, Jackson D, Clayton BE (1976) Hormonal changes in thalassemia major. Arch Dis Child 51:828–836

  12. 12.

    Gamberini MR, Fortini M, Gilli G, Testa MR, De Sanctis V (1998) Epidemiology and chelation therapy effect on glucose homeostasis in thalassaemic patients. J Pediatr Endocrinol Metab 11:867–869

  13. 13.

    Gulati R, Bhatia V, Agarwal SS (2000) Early onset of endocrine abnormalities in β-thalassemia major in a developing country. J Pediatr Endocrinol Metab 13:651–656

  14. 14.

    Haffner SM, Gonzales C, Miettinen H, Kennedy E, Stern MP (1996) A prospective analysis of the HOMA model. Diabetes Care 19:1138–1141

  15. 15.

    Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK (1986) Hyperinsulinemia in a population at high-risk of non-insulin dependent diabetes mellitus. N Engl J Med 315:220–224

  16. 16.

    McIntosh N (1976) Endocrinopathy in thalassemia major. Arch Dis Child 51:195–201

  17. 17.

    Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane WV (1988) Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 318:809–814

  18. 18.

    Mohammadian S, Bazrafshan HR, Sadaghi-Nejad A (2003) Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab 16:957–964

  19. 19.

    Nathalang O, Arnutti P, Nillakupt K (2004) Thalassemia screening among Royal Thai Army medical cadets. Mil Med 169:274–276

  20. 20.

    Nutrition Division, Department of Health Ministry of Public Health, Thailand (1999) National growth references for children under 20 years of age. Nutrition Division, Department of Health Ministry of Public Health, Bangkok

  21. 21.

    Pansatiankul B, Saisorn S (2003) A community-based thalassemia prevention and control model in northern Thailand. J Med Assoc Thai 86[Suppl 3]:S576–S582

  22. 22.

    Pantelakis S (1994) Thyroid disorders and diabetes mellitus as complications of thalassemia major. Acta Paediatr Suppl 406:111–113

  23. 23.

    Pappas S, Donohue SM, Denver AE, Mohamed-Ali V, Goubet S, Yudkin JS (1996) Glucose intolerance of thalassemia major is related to insulin resistance and hepatic dysfunction. Metabolism 45:652–657

  24. 24.

    Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S (2002) Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346:802–810

  25. 25.

    Tiosano D, Hochberg Z (2001) Endocrine complications of thalassemia. J Endocrinol Invest 24:716–723

  26. 26.

    Tuchinda C, Likitmaskul S, Unachak K, Panamonta O, Patarakijvanich N, Chetthakul T (2002) The epidemiology of type 1 diabetes in Thai children. J Med Assoc Thai 85:648–652

Download references

Author information

Correspondence to Somchit Jaruratanasirikul.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jaruratanasirikul, S., Chareonmuang, R., Wongcharnchailert, M. et al. Prevalence of impaired glucose metabolism in β-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy. Eur J Pediatr 167, 873–876 (2008). https://doi.org/10.1007/s00431-007-0602-0

Download citation

Keywords

  • Diabetes mellitus
  • Glucose metabolism
  • Impaired glucose tolerance
  • Thalassemia